Drug Eluting Stent (DES) in Primary Angioplasty

NCT00759850 | Completed Phase 2

• 1 other identifier: AOM_DES01
• Study Type: interventional
• Target: 270
• Locations: 1 country
• Sites: 1

Brief Summary

Stent implantation is the best treatment in patients with acute myocardial infarction (STEMI) referred for primary angioplasty (pPCI). However the occurrence of in stent restenosis is responsible for the need of repeat intervention. Both Sirolimus-eluting stents (SES) and Paclitaxel-eluting stents (PES) have been proven to virtually abolish in-stent restenosis in elective patients in simple e more complex lesions. Both SES and PES have raised concerns regarding occurrence of late stent thrombosis, especially in complex lesion subsets or in high risk patients. The PaclitAxel or Sirolimus-Eluting Stent vs Bare Metal Stent in primary angioplasty (PASEO) trial was a prospective, single-center, randomized trial evaluating the benefits of SES or PES as compared to BMS implantation in patients undergoing primary angioplasty for acute STEMI. From 1 October 2003 we randomized with 1:1:1 ratio, 270 patients with STEMI and treated with pPCI, to implantation of a bare metal stent (BMS n=90), PES (n=90) or SES (n=90).

Conditions

Acute Myocardial Infarction

Keywords

Acute Myocardial Infarction; Drug Eluting Stent; Primary PCI

Outcome Measures

Primary Outcomes (1)

• The primary end point was target lesion revascularization (TLR) at 1-year follow-up

  1 year

Secondary Outcomes (1)

• Cumulative combined incidence of death and/or reinfarction at 2 year; Cumulative incidence of in-stent thrombosis at 2 year; 3) Major Adverse Cardiac Events (MACE) (combined death and/or reinfarction and/or TLR) at 2 years

  2 year

Study Arms (3)

A

ACTIVE COMPARATOR

Patient with ST elevation myocardial infarction randomly assigned to receive a Bare Metal Stent n=90)

Device: Drug Eluting Stent (DES)

B

EXPERIMENTAL

Patient with ST elevation myocardial infarction randomly assigned to receive a Paclitaxel Eluting Stent (n=90)

Device: Drug Eluting Stent (DES)

C

EXPERIMENTAL

Patient with ST elevation myocardial infarction randomly assigned to receive a Sirolimus Eluting Stent (n=90)

Device: Drug Eluting Stent (DES)

Interventions

Drug Eluting Stent (DES) DEVICE

Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.

Also known as: Primary Angioplasty, Cypher, Taxus

A; B; C

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinical symptoms of STEMI, with initial onset of chest pain within the past 12 hours, an ECG demonstrating \> 0.1 mV ST-segment elevation in 2 or more contiguous leads or documented new left bundle-branch block and were suitable candidates for percutaneous revascularization.

You may not qualify if:

• Active internal bleeding or a history of bleeding diathesis within the previous 30 days
• An history of intracranial hemorrhage
• Intracranial neoplasm
• Arteriovenous malformation or aneurysm
• Known allergy to sirolimus
• Paclitaxel
• Heparin, aspirin, or clopidogrel
• An history of stroke within 30 days or any history of hemorrhagic stroke
• History, symptoms, or findings suggestive of aortic dissection, fibrinolytic therapy within 24 hours
• History of thrombocytopenia, pregnancy, patients on warfarin or acenocoumarol within the last seven days
• Inability to obtain the informed consent

Sponsors & Collaborators

• San Giuseppe Moscati Hospital: lead

Study Sites (1)

U.O. Cardiologia/UTIC

Avellino, 83100, Italy

Location

Related Publications (2)

• Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G, De Luca G. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009 Oct;158(4):e43-50. doi: 10.1016/j.ahj.2009.03.016.

  PMID: 19781402 DERIVED

• Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) Randomized Trial. JACC Cardiovasc Interv. 2009 Jun;2(6):515-23. doi: 10.1016/j.jcin.2009.03.012.

  PMID: 19539255 DERIVED

MeSH Terms

Interventions

Drug-Eluting Stents

Intervention Hierarchy (Ancestors)

Stents; Prostheses and Implants; Equipment and Supplies

Study Officials

• Emilio Di Lorenzo, MD PhD

  Division of Cardiology A.O. Moscati Avellino Italy

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER

Study Record Dates

• First Submitted: September 24, 2008
• First Posted: September 25, 2008
• Study Start: October 1, 2003
• Primary Completion: October 1, 2005
• Study Completion: December 1, 2007
• Last Updated: September 25, 2008

Record last verified: 2008-09

Locations

IT (1)